Safely Guiding the Immune System to Fight Disease
Eradivir is developing drugs that bind to diseased cells, serving as a beacon to guide the immune system.
Our Vision
Our goal is to focus the power of the immune system to treat disease. Our small molecule based Bispecific Antigenic immuno-Therapy (BAiT) technology tethers a patient’s immune cells specifically to a diseased cell facilitating its rapid and selective destruction. With a toolkit of these small molecule immunotherapies, we will be able to develop pharmaceuticals to treat and cure multiple diseases, including viral infections and cancer.
Rethinking Influenza
Our lead molecule, EV25, has been shown to be more effective than the current standard of care against all strains of influenza. EV25 functions by linking infected cells to two anti-hapten antibodies, thereby recruiting the body's innate immune system to rapidly clear the disease.
Learn more about EV25Eradivir has assembled a team of seasoned industry leaders, world class scientists and expert advisors.
